STAT5A and breast cancer: To build preclinical evidence for clinical trials to test inhibitors of STAT5 signaling for lowering breast cancer risk in women who have undergone a late-age pregnancy or have abnormally high baseline levels of pSTAT5 signaling, we tested the efficacy of pharmacological inhibitors in preventing mammary tumorigenesis in our mouse model.